Nurix Therapeutics (NRIX) Non-Current Deffered Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Non-Current Deffered Revenue data on file, last reported at $7.6 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $7.6 million, down 68.6% year-over-year; the trailing twelve-month figure through Feb 2026 was $7.6 million (down 68.6% YoY), and the FY2025 annual result was $10.0 million, down 61.8% from the prior year.
• Non-Current Deffered Revenue slipped to $7.6 million in Q1 2026 per NRIX's latest filing, from $10.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $55.4 million in Q1 2022 and troughed at $7.6 million in Q1 2026.
• A 5-year average of $28.4 million and a median of $26.2 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deffered Revenue tumbled 75.35% in 2023, then jumped 191.5% in 2024.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $36.0 million in 2022, then advanced by 25.15% to $45.0 million in 2023, then plunged by 41.79% to $26.2 million in 2024, then plunged by 61.8% to $10.0 million in 2025, then fell by 24.23% to $7.6 million in 2026.
• Business Quant data shows NRIX's Non-Current Deffered Revenue at $7.6 million in Q1 2026, $10.0 million in Q4 2025, and $15.2 million in Q3 2025.